In line with the results of the PCSK9 drug‐target control MR analyses, a genetically proxied inhibition in the PCSK9 protein level was associated with a lower risk of CHD in two sets of PCSK9 cis‐pQTLs. Here, PCSK9 is linked to coronary artery disorder.